[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"segmentectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:segmentectomy":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,39,65,86,109,138,168,196,220],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100641522","evaluating-the-association-of-force-feedback-with-outcomes-after-lung-resection-using-the-da-vinci-multiport-system-100641522",false,"NCT07660900","Evaluating the Association of Force Feedback With Outcomes After Lung Resection Using the da Vinci Multiport System","Inclusion Criteria:\n\n* Ages 18 years or older\n* Undergoing robotic-assisted anatomic lung resection (lobectomy or segmentectomy) at The Ohio State University Wexner Medical Center\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Subject is pregnant or suspected to be pregnant or breastfeeding\n* ECOG Performance status \\> 2\n* Do not qualify for ERAS protocol\n* Undergoing an emergent procedure\n* Undergoing non-anatomic lung resection\n* Undergoing pneumonectomy\n* Previous ipsilateral thoracic surgery (open, video-assisted thoracoscopic or robotic)\n* Planned to undergo major concomitant surgery for the treatment of a different medical condition than was originally planned\n* Non-English speaking","ALL","18 Years",{"count":18,"type":19},270,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to study patient outcomes based on the use of Force Feedback instruments during robotic-assisted lung resection. Force Feedback technology describes the physical forces a surgeon senses when pushing and pulling structures inside the body during robotic-assisted surgery.",[23,24,25],"Lobectomy","Segmentectomy","Force Measurement","RECRUITING","2026-06-16",{"date":29,"type":30},"2026-06-22","ACTUAL",{"date":32,"type":30},"2025-09-05",{"date":34,"type":19},"2027-12-31",{"name":36,"class":37},"Ohio State University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":38},"100641875","pre-incisional-infiltration-with-ropivacaine-plus-diprospan-for-relieving-postoperative-pain-after-thoracoscopic-surgery-100641875","NCT07626489","Pre-incisional Infiltration With Ropivacaine Plus Diprospan for Relieving Postoperative Pain After Thoracoscopic Surgery","The Efficacy and Safety of Pre-incisional Infiltration With Ropivacaine Plus Diprospan in Patients Undergoing Video-assisted Thoracoscopic: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective Video-assisted thoracoscopic surgery for wedge resection, segmentectomy and lobectomy of the lungs under general anesthesia;\n2. 8 to 64 years old\n3. American Society of Anesthesiologists (ASA) physical status of I-III\n4. Patients must be able to understand the nature and potential personal consequences of the clinical trial and cooperate with follow-up investigations\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of allergies to experimental drugs such as opioids or steroids;\n2. Alcohol abuse; Long term use of opioid drugs (exceeding 2 weeks or 3 days per week for more than 1 month); Suspected use of sedatives and analgesics; Use analgesic drugs within 24 hours before surgery; Patients undergoing steroid therapy;\n3. Serious neurological disorders, severe liver and kidney dysfunction, heart failure, etc;\n4. Unable to use pain assessment scale;\n5. Pregnant or lactating patients.","64 Years",{"count":48,"type":19},100,"INTERVENTIONAL",[51],"NA","Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy, but it is still reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process. If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Acute pain after VATS is mainly caused by the release of inflammatory mediators after soft tissue injury at the surgical site, which activates peripheral pain receptors and leads to abnormal action potentials transmitted along A δ and C fibers. Inflammatory mediators released from the soft tissues around incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization.\n\nIncisional infiltration is the simplest, safest, and most effective anesthesia method for preventing incision pain after VATS, but even using long-acting local anesthetics, the effectiveness of postoperative analgesia can only last for a relatively short period of time. To improve the efficiency of local incision infiltration in postoperative analgesia, at least two issues need to be addressed: prolonging the duration of analgesia and reducing inflammation of nerve surrounding tissues. Numerous studies have shown that glucocorticoids not only can achieve anti-inflammatory and analgesic effects by inhibiting inflammatory cytokines and inflammatory responses but also can prolong the duration of action of local anesthetics. Preemptive incisional infiltration using local anesthetics with corticosteroids which have potent local anti-inflammatory properties may play a key role in preventing or reducing postoperative pain. The objective of this trial is to determine whether preemptive incisional infiltration with ropivacaine plus diprospan is superior to ropivacaine alone in relieving postoperative pain for adults undergoing VATS. The investigators also compare the effects of the two intervention measures on postoperative pain management, patient safety, and recovery quality.",[54,55,24,23,56],"Video-assisted Thoracoscopic Surgery (VATS)","Wedge Resection","Infiltration Anesthesia",{"date":58,"type":30},"2026-06-17",{"date":60,"type":19},"2026-05-30",{"date":62,"type":19},"2028-05-30",{"name":64,"class":37},"Beijing Tiantan Hospital",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":72,"targetDuration":4,"studyType":49,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":38},"100642912","pre-incisional-infiltration-with-ropivacaine-plus-triamcinolone-for-relieving-postoperative-pain-after-thoracoscopic-surgery-100642912","NCT07603921","Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery","The Efficacy and Safety of Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone in Patients Undergoing Video-assisted Thoracoscopic: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective thoracoscopic wedge resection, segmentectomy, and lobectomy under general anesthesia;\n2. Ages 18 to 64 years old\n3. American Society of Anesthesiologists (ASA) physical status of I-III\n4. Patients must be able to understand nature and potential personal consequences of the clinical trial and cooperation with follow-up investigations\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of allergies to experimental drugs such as opioids or steroids;\n2. Alcohol abuse; Long term use of opioid drugs (exceeding 2 weeks or 3 days per week for more than 1 month); Suspected use of sedatives and analgesics; Use analgesic drugs within 24 hours before surgery; Patients undergoing steroid therapy;\n3. Serious neurological disorders, severe liver and kidney dysfunction, heart failure, etc;\n4. Unable to use pain assessment scale;\n5. Pregnant or lactating patients.",{"count":48,"type":19},[51],"Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy, but it is still reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process. If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Acute pain after VATS is mainly caused by the release of inflammatory mediators after soft tissue injury at the surgical site, which activates peripheral pain receptors and leads to abnormal action potentials transmitted along A δ and C fibers. Inflammatory mediators released from the soft tissues around incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization. Incisional infiltration is the simplest, safest, and most effective anesthesia method for preventing incision pain after laparoscopic surgery but even using long-acting local anesthetics, the effectiveness of postoperative analgesia can only last for a relatively short period of time. To improve the efficiency of local incision infiltration in postoperative analgesia, at least two issues need to be addressed: prolonging the duration of analgesia and reducing inflammation of nerve surrounding tissues.\n\nNumerous studies have shown that glucocorticoids not only can achieve anti-inflammatory and analgesic effects by inhibiting inflammatory cytokines and inflammatory responses but also can prolong the duration of action of local anesthetics. The investigators conducted a multicenter, prospective, randomized controlled clinical study to explore whether preemptive incisional infiltration with ropivacaine plus triamcinolone is superior to ropivacaine alone in relieving postoperative pain for adults undergoing VATS. The investigators also compare the effects of the two intervention measures on postoperative pain management, patient safety, and recovery quality.",[54,55,24,76,77,78],"Lobectomy of the Lungs","Incisional Infiltration","Triamcinolone","2026-06-15",{"date":27,"type":30},{"date":82,"type":30},"2026-06-01",{"date":84,"type":19},"2028-03-31",{"name":64,"class":37},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":93,"targetDuration":4,"studyType":49,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100642646","the-efficacy-and-safety-of-loxoprofen-sodium-patch-in-relieving-postoperative-pain-after-thoracoscopic-surgery-100642646","NCT07591220","The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Thoracoscopic Surgery","The Efficacy and Safety of Incisional Preemptive Analgesia Using Loxoprofen Sodium Patch in Patients Undergoing Thoracoscopic Surgery: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective Video-assisted thoracoscopic surgery for wedge resection, segmentectomy and lobectomy of the lungs under general anesthesia;\n2. 8 to 64 years old;\n3. American Society of Anesthesiologists (ASA) physical status of I-III;\n4. Patients must be able to understand the nature and potential personal consequences of the clinical trial and cooperate with follow-up investigations\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of chronic pain syndrome of any cause and mental illness;\n2. Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery;\n3. History of hypertension (Grade 3, extremely high risk);\n4. Pregnancy or breastfeeding;\n5. Extreme body mass index (BMI) (\\\u003C 15 or \\> 35);\n6. Participation in another interventional trial that interferes with the intervention or outcome of this trial;\n7. Digestive system diseases (such as peptic ulcers, gastric bleeding);\n8. Patients with coronary artery disease;\n9. Patients with renal impairment (serum creatinine \\> 176 µmol\u002FL) and abnormal liver function(alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN);\n10. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran;\n11. Patients with a history of allergy to anyone of the study drugs;",{"count":94,"type":19},156,[51],"Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy, but it is still reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process. If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Acute pain after VATS is mainly caused by the release of inflammatory mediators after soft tissue injury at the surgical site, which activates peripheral pain receptors and leads to abnormal action potentials transmitted along A δ and C fibers. Inflammatory mediators released from the soft tissues around incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization. Therefore, drugs with potent local anti-inflammatory properties such as Loxoprofen Sodium may play a key role in preventing or reducing postoperative pain. The investigators conducted a multicenter, prospective, randomized controlled clinical study to explore the use of Loxoprofen Sodium Patch for preoperative local incision analgesia in VATS patients. The investigators aim to observe whether this method can effectively alleviate postoperative incision pain, reduce the dosage of postoperative analgesics and the side effects caused using postoperative analgesics, improve patient satisfaction, and provide new ideas for postoperative analgesia in VATS patients, promoting rapid recovery after VATS.",[54,98,99,100,55,24,23],"Loxoprofen Sodium Patch","Local Incision","Postoperative Pain","NOT_YET_RECRUITING","2026-06-07",{"date":104,"type":30},"2026-06-10",{"date":82,"type":19},{"date":107,"type":19},"2028-04-30",{"name":64,"class":37},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":49,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":38},"100554251","segmentectomy-after-induction-therapy-saint-100554251","NCT06496659","Segmentectomy After Induction Therapy (SAINT)","Segmentectomy After Induction Therapy (SAINT): Phase II Single Arm Trial Evaluating Segmentectomy in Accomplishing R0 Resection for Patients With Lung Cancer Treated With Neoadjuvant Therapy","SAINT","Inclusion Criteria:\n\n* Patients must have histologically confirmed non-small-cell lung cancer that is clinically staged as ≤ycT1cN0M0 (tumor size 3cm or less on greatest dimension measured by cross-sectional imaging) after receiving induction therapy.\n* Patients may have received any regimen of neoadjuvant chemotherapy, neoadjuvant immunotherapy, or neoadjuvant chemoimmunotherapy.\n* Patients must have the ability to understand and the willingness to sign a written informed consent document.\n* Patients must be age ≥ 18 years.\n* Patients must exhibit a\u002Fan ECOG (Eastern Cooperative Oncology Group) performance status of \\\u003C3.\n* Patients must have adequate organ function as defined below: These are guidelines that may or should be modified based on protocol-specific or drug development-specific needs.\n\nTable 1: Measures of Adequate Organ Function. FEV1 or DLCO ≥40% (DLCO: diffusing capacity of lung for carbon monoxide)\n\n* For patients with a known history of Human immunodeficiency virus (HIV), infected patients on effective anti-retroviral therapy must have a viral load undetectable for 6 months prior to registration.\n* For patients with a known history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be considered a candidate for surgical resection under general anesthesia.\n* Females of child-bearing potential (FOCBP) must have a negative pregnancy test prior to registration on study.\n\nNOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n* Has not undergone a hysterectomy or bilateral oophorectomy\n* Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n\nExclusion Criteria:\n\n* Patients who have had prior lung resection or thoracic surgery.\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia.\n* Patients who are receiving any other investigational agents.\n* Patients with evidence of distant metastases including brain metastases will be excluded from this study because they will not benefit from surgical resection.\n* Patients that do not have documented consensus agreement on the feasibility of anatomic sublobar resection (segmentectomy) from at least 2 study surgeons will not be enrolled.\n* Patients with pre-induction therapy tumor involving greater than 1 lobe.\n* Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible:\n\n  * Hypertension that is not controlled on medication\n  * Ongoing or active infection requiring systemic treatment\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n  * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints\n* Female patients who are pregnant. Pregnant patients are excluded from this study because the study protocol requires frequent cross-sectional imaging with potential for teratogenic effects.\n* Patients with another malignancy within 3 years (except for non-melanoma skin cancer, CIS of cervix (a preinvasive carcinomatous change of the cervix), superficial bladder cancer). Patients with prior malignancies are excluded to isolate overall survival outcomes.\n* Patients with active smoking status or cessation \\\u003C4 weeks prior to surgical resection.\n* Patients with biopsy positive hilar or mediastinal lymph nodes following induction therapy detected by EBUS (endobronchial ultrasound), mediastinoscopy, or intraoperative sampling.","89 Years",{"count":119,"type":19},25,[51],"The primary objective will be to determine the feasibility of performing a high-quality sublobar anatomic resection (segmentectomy) with R0 margin status on final pathology for patients who received induction therapy for NSCLC and are downstaged to ≤ycT1cN0M0 (TDi 3cm or less). T1c is tumor staging 1 and c stands for tumor is considered larger than 2cm but no larger than 3cm across; N0 is No regional lymph node metastasis; M0 is No distant metastasis.",[24],[124,125,126,127,128],"Non-Small Cell Lung Cancer","Neoadjuvant therapy","Anatomic resection","Post-induction therapy","Surgical intervention","2026-05-21",{"date":131,"type":30},"2026-05-26",{"date":133,"type":30},"2024-08-02",{"date":135,"type":19},"2029-07-30",{"name":137,"class":37},"Northwestern University",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":15,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":49,"phases":148,"briefSummary":149,"conditions":150,"keywords":156,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":38},"100555754","auricular-acupressure-in-prehabilitation-100555754","NCT06516198","Auricular Acupressure in Prehabilitation","A Pilot Study of the Utility of Auricular Acupressure in Enhancing Prehabilitation Benefits in Candidates for Thoracic Surgery.","Inclusion Criteria\n\n* Being considered for major lung surgery\n* Surgery is not scheduled for at least 2 weeks\n* Age ≥ 50 years\n* Able to understand English at a 4th grade level\n* No known contraindications to prehabilitation (strength, endurance, balance exercises)\n* Able to provide informed consent for participation\n* Has an adult care partner who will be available and capable of placing seeds\n* Has access to smart phone for communication and image sharing\n* Underwent frailty screening (given any score)\n* Able to perform spirometry testing in clinic\n\nExclusion Criteria:\n\n* Allergy to Vaccaria seeds\n* Medical condition affecting either ear preventing use of auricular acupressure such as eczema, frostbite, sunburn","50 Years",{"count":147,"type":19},40,[51],"Complementary medicine is recognized for its ability to enhance appetite, increase energy, reduce anxiety, decrease pain, and improve sleep, among many other benefits. Acupuncture is among the most frequent types of complementary medicine practiced in the US, and Medicare currently includes back pain as a reimbursable indication for this therapy. Acupuncture-related therapies may enhance efforts at prehabilitation in candidates for major lung resection.",[151,152,153,154,55,24,23,155],"Frailty","Thoracic","Prehabilitation","Lung Surgery","Pneumonectomy; Status",[157,158],"accupressure","vaccaria seeds","2025-12-02",{"date":161,"type":30},"2025-12-09",{"date":163,"type":30},"2025-07-21",{"date":165,"type":19},"2027-06-20",{"name":167,"class":37},"University of Chicago",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":195},"100479664","personalized-postoperative-pain-management-following-thoracic-surgery-in-adults-100479664","NCT05525923","Personalized Postoperative Pain Management Following Thoracic Surgery in Adults","Pharmacogenetics and Pharmacokinetics of Oxycodone to Personalize Postoperative Pain Management Following Thoracic Surgery in Adults","Inclusion Criteria:\n\n* \\>18 years\n* American Society of Anesthesiologists (ASA) Physical Status 1, 2, 3\n* Undergoing thoracic surgery (TS; pneumonectomy, lobectomy and segmentectomy)\n\nExclusion Criteria:\n\n* Children (\\\u003C18 years)\n* Pregnant women\n* American Society of Anesthesiologists (ASA) Physical Status 4 or above\n* Non-English speaking\n* Outpatient surgery\n* Concomitant additional surgical procedures\n* Significant liver and kidney dysfunction\n* Significant cardiorespiratory compromise\n* Patients with polysubstance use (e.g., cocaine, marijuana, amphetamine, etc.)","99 Years",{"count":177,"type":19},200,"The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research. This research focuses on two of the most commonly used oral opioid analgesics, oxycodone, and methadone, in adults following thoracic surgery. Major inpatient thoracic surgeries (TS) for lung disease are common and extremely painful surgeries and are associated with sever post-surgical pain, high incidence of chronic post-surgical pain (CPSP), excess opioid use, costly immediate postoperative opioid adverse events (AEs), and long hospital stays. This study is aiming to develop proactive risk prediction algorithms for precision surgical pain relief in adult TS patients through comparison of actual clinical outcomes with standard of care to predicted outcomes based on personalized risk assessments.",[180,181,23,24],"Thoracic Surgery","Pneumonectomy",[183,184],"Pain Management","Opioid Use","2025-04-28",{"date":187,"type":30},"2025-05-01",{"date":189,"type":30},"2023-11-30",{"date":191,"type":19},"2028-03-01",{"name":193,"class":194},"OpalGenix, Inc","INDUSTRY",4,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":49,"phases":206,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":38},"100564883","phase-3-segmentectomy-for-solid-dominant-lung-cancer-100564883","NCT06634966","Segmentectomy for Solid-dominant Lung Cancer","Segmentectomy for Solid-dominant GGO-featured Invasive Lung Cancer With Size of 2-3cm: a Single-arm, Multi-center, Phase III Trial","Inclusion Criteria:\n\n* Patients who sign the informed consent form and are willing to complete the study according to the plan;\n* Aged from 18 to 80 years old;\n* ECOG equals 0 or 1;\n* Not receiving lung cancer surgery before;\n* Confirmed to be invasive lung adenocarcinoma intraoperatively or postoperatively;\n* Ground glass-dominant lung nodules\n* Consolidation-to-tumor ratio (CTR) ranges from 0.5 to 1, and tumor size ranges from 2 to 3cm;\n* cN0 without distant metastasis;\n* Tumors could be completely resected assed by surgeons;\n* Not receiving chemotherapy or radiotherapy before.\n\nExclusion Criteria:\n\n* CTR is not 0.5-1, or size is not 2-3cm;\n* Tumors could not be completely resected assed by surgeons;\n* Not lung adenocarcinoma diagnosed cytologically or pathologically;\n* Receiving lung cancer surgery before;\n* Receiving radiotherapy or chemotherapy.","80 Years",{"count":205,"type":19},277,[207],"PHASE3","This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1025. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for solid-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are:\n\n* The 5-year disease-free survival of patients having solid-dominant invasive lung cancer with size of 2-3cm;\n* The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.",[24,210],"Lung Adenocarcinoma","2024-10-09",{"date":213,"type":30},"2024-10-10",{"date":215,"type":30},"2024-07-01",{"date":217,"type":19},"2027-06-30",{"name":219,"class":37},"Fudan University",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":203,"enrollmentInfo":227,"targetDuration":4,"studyType":49,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":38},"100494409","phase-3-segmentectomy-for-ground-glass-dominant-invasive-lung-cancer-ectop-1012-100494409","NCT05717803","Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)","Segmentectomy for Ground Glass-dominant Invasive Lung Cancer With Size of 2-3cm: a Single-arm, Multi-center, Phase III Trial","Inclusion Criteria:\n\n* Patients who sign the informed consent form and are willing to complete the study according to the plan;\n* Aged from 18 to 80 years old;\n* ECOG equals 0 or 1;\n* Not receiving lung cancer surgery before;\n* Confirmed to be invasive lung adenocarcinoma intraoperatively or postoperatively;\n* Ground glass-dominant lung nodules\n* Consolidation-to-tumor ratio (CTR) ranges from 0 to 0.5, and tumor size ranges from 2 to 3cm;\n* cN0 without distant metastasis;\n* Tumors could be completely resected assed by surgeons;\n* Not receiving chemotherapy or radiotherapy before.\n\nExclusion Criteria:\n\n* CTR is not 0-0.5, or size is not 2-3cm;\n* Tumors could not be completely resected assed by surgeons;\n* Not lung adenocarcinoma diagnosed cytologically or pathologically;\n* Receiving lung cancer surgery before;\n* Receiving radiotherapy or chemotherapy.",{"count":228,"type":19},307,[207],"This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1012. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for ground glass-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are:\n\n* The 5-year disease-free survival of patients having ground glass-dominant invasive lung cancer with size of 2-3cm;\n* The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.",[24,210],"2024-05-30",{"date":234,"type":30},"2024-06-03",{"date":236,"type":30},"2023-02-15",{"date":238,"type":19},"2029-12-31",{"name":219,"class":37}]